Research Article
The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis
Table 1
Preoperative and postoperative characteristics of the 172 matched patients.
| | Characteristic | Group 1 | Group 2 | | Adjuvant ADT | No adjuvant ADT |
| | Patients number | 86 | 86 | | Median age (years) | 66.2 | 66.6 | | Median Follow-up (months) | 69 | 66 | | Mean PSA, ng/mL (range) | 31.5 (3–119) | 28.4 (2.78–159) |
| | Clinical stage, 1997 TNM, (number (%)) | | | | ≤cT2 | 36 (41.8%) | 48 (55.8%) | | cT3 | 49 (57.0% ) | 37 (43.0%) | | cT4 | 1 (1.2 %) | 1 (1.2%) |
| | Biopsy Gleason score (number (%)) | | | | ≤6 | 36 (41.8%) | 44 (51.2%) | | 7 | 39 (45.3%) | 32 (37.2%) | | ≥8 | 11 (12.9%) | 10 (11.6%) |
| | Pathol. stage, 1997 TNM (number (%)) | | | | pT2 | 4 (4.7%) | 9 (10.5%) | | pT3a | 28 (32.5%) | 29 (33.7%) | | pT3b | 50 (58.1%) | 45 (52.3%) | | pT4 | 4 (4.7%) | 3 (3.5%) |
| | Pathol. Gleason score (number (%)) | | | | ≤6 | 34 (39.5%) | 34 (39.5%) | | 7 | 39 (45.4%) | 39 (45.4%) | | ≥8 | 13 (15.1%) | 13 (15.1%) |
| | Surgical margins (number (%)) | | | | Positive | 62 (72.1%) | 66 (76.7%) | | Negative | 24 (27.9%) | 20 (23.3%) |
| | Salvage therapy | | | | ADT | 0 (0.0%) | 25 (29.1%) | | Radiotherapy | 3 (3.5%) | 9 (10.5%) |
|
|
PSA: prostate-specific antigen; ADT: androgen deprivation therapy.
|
